This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           July 22, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

HPV genomes show greater diversity than expected among cervical cancer patients
GenomeWeb (Free login may be required)
The genomes of human papillomaviruses in cervical cancer patients are more diverse than expected, even within the same patient, according to researchers from the University of São Paulo in Brazil. The findings, published this month in Infection, Genetics and Evolution could have implications for eventually understanding why some cervical lesions become malignant.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Annual Meeting Call for Abstracts and Surgical Films open July 20-Sept. 15
The Call for Abstracts and Surgical Films for the 2016 SGO Annual Meeting on Women’s Cancer is now open and closes at 11:59 p.m. CT Tuesday, Sept. 15. The 47th Annual Meeting will take place March 19-22, 2016, at the San Diego Convention Center in San Diego, CA.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN AND BREAST CANCER


FDA grants orphan drug designation to immunotherapeutic agent for ovarian cancer
Healio
The Food and Drug Administration granted orphan drug designation to DPX-Survivac, an immunotherapeutic agent designed to treat all stages of ovarian cancer, according to a press release from the drug’s manufacturer. The vaccine, which consists of survivin-based peptide antigens, activates a response to the tumor antigen survivin, a protein found in the tumors of more than 90 percent of patients with ovarian cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
SPONSORED CONTENT


Dual targeted Rx tested in breast, ovarian cancers
Clinical Oncology News
Substantial response rates were achieved in early-phase trials in women with high-grade serous ovarian or triple-negative breast cancers when a PARP inhibitor and a P13K inhibitor were given as combined treatment. Toxicities were manageable, providing evidence that the synergy seen with this strategy in the experimental setting may be viable in the clinic. In this study, the PARP inhibitor, olaparib , which already has an indication for advanced germline BRCA (gBRCA)-mutated ovarian cancer, was combined with the investigational P13K inhibitor BKM120 (buparlisib).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Scientists solve breast and ovarian cancer genetic mystery
Medical Xpress
Following a five-year study in nematode worms, researchers have uncovered how key proteins can switch on a protein called RAD51, allowing it to repair cancer-causing DNA damage in cells. Women with faulty RAD51 and BRCA1 and BRCA2 genes are at higher risk of developing breast and ovarian cancer. Scientists already knew how proteins produced by these genes work hand-in-hand to fix DNA damage, and why faults can lead to disease. The study was published recently in the journal Cell.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


HPV


Early push to require the HPV vaccine may have created barrier to uptake
NPR
Nine years after it was first approved in June 2006, the HPV vaccine has had a far more sluggish entree into medical practice than other vaccines at a similar point in their history, according to a report in JAMA. This might not surprise those who remember the early days of the human papillomavirus vaccine, which was targeted at girls aged 11 and 12 to prevent a sexually transmitted infection that causes cancer — but which opponents quickly branded as a vaccine that would promote teenage promiscuity.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


  Ovarian cancer updates from ASCO 2015:

4 prominent experts in ovarian cancer met in Chicago to provide perspectives related to progress made toward personalized therapy. More
 


GENETIC COUNSELING


Telegenetics use in presymptomatic genetic counselling: patient evaluations on satisfaction and quality of care
European Journal of Human Genetics
In recent years, online counselling has been introduced in clinical genetics to increase patients’ access to care and to reduce time and cost for both patients and professionals. Most telegenetics reports so far evaluated online oncogenetic counselling at remote health centres in regions with large travelling distances, generally showing positive patient outcomes. We think online counselling — including the use of supportive tools that are also available during in-person counselling — of presymptomatic patients in their homes can also be feasible and valuable for patients in relatively small regions.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




BREAST CANCER


Uncovering the role of progesterone in the treatment of breast cancer
Cancer Network
Clinicians have long observed that breast cancer patients who are both estrogen receptor (ER)-positive and progesterone receptor (PR)-positive have better clinical outcomes. These patients tend to respond better to treatment and have a lower risk of relapse, even though they are treated with the same hormone therapy as their ER-positive, PR-negative counterparts. Now, researchers from the United Kingdom and Australia have uncovered the molecular underpinnings of why upregulation of both hormone receptors results in better tumor control. Their results, published in the July 16 issue of Nature, suggest that hormone therapy with progesterone could be used in the treatment of ER-positive, PR-positive disease, which makes up about half of all diagnosed breast cancers
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 15, 2015
July 8, 2015
July 1, 2015
June 24, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063